<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880721</url>
  </required_header>
  <id_info>
    <org_study_id>301jrcsk4</org_study_id>
    <nct_id>NCT03880721</nct_id>
  </id_info>
  <brief_title>By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation</brief_title>
  <official_title>By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Developing a radiomics model to predict the prognosis of patients with hepatocellular
      carcinoma after microwave ablation to provide advice for their treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AUC value</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>Utilizing area under curve to judge the accurency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>diagnosis sensitivity of intelligent ultrasound analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>diagnosis specificity of intelligent ultrasound analysis</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Good prognosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor prognosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Recurrence</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Not Recurrence</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Survival</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Death</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave abaltion</intervention_name>
    <description>Use microwave ablation to treat hepatocellular carcinoma</description>
    <arm_group_label>Death</arm_group_label>
    <arm_group_label>Good prognosis</arm_group_label>
    <arm_group_label>Not Recurrence</arm_group_label>
    <arm_group_label>Poor prognosis</arm_group_label>
    <arm_group_label>Recurrence</arm_group_label>
    <arm_group_label>Survival</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary hepatocellular carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary hepatocellular carcinoma in the department of interventional
             ultrasound, PLA general hospital, who accept MWA therapy for HCC

        Inclusion criteria:

          1. Primary hepatocellular

          2. No other treatments ware performed before microwave ablation

          3. Patient has been clinically diagnosed with HCC definitely, and have a definite
             operational indication

          4. No extrahepatic manifestations and no evidence of vessel invasion and bile duct
             thrombi

        Exclusion Criteria:

          -  Exclusion criteria:

               1. Non-primary hepatocellular carcinoma or hepatic metastases

               2. Accept other treatment before microwave ablation

               3. Extrahepatic metastasis, vessel invasion or bile duct thrombi
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie Yu, Dr</last_name>
    <phone>8610-66939530</phone>
    <email>yu-jie301@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Liang, Dr</last_name>
    <phone>8610-66939530</phone>
    <email>liangping301@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Liang, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Ping Liang</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>radiomics</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

